Outcome of second-line chemotherapy for biliary tract cancer

European Journal of Cancer

Volumn 49, Issue 6, 2013, Pages 1511-

  Bridgewater, John ^a   Palmer, Daniel ^a   Cunningham, David ^a   Iveson, Tim ^a   Gillmore, Roopinder ^a   Waters, Justin ^a   Harrison, Mark ^a   Wasan, Harpreet ^a   Corrie, Pippa ^a   Valle, Juan ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; OXALIPLATIN;

BILIARY TRACT CANCER; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; FUNCTIONAL STATUS; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION;

BILIARY TRACT NEOPLASMS; FEMALE; HUMANS; MALE;

EID: 84875722822     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.11.024     Document Type: Letter

References (2)

1. T. Walter, A.M. Horgan, and M. McNamara Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study Eur J Cancer 49 2013 329 335
2. J. Valle, H. Wasan, and D.H. Palmer Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 2010 1273 1281